News
AMIX
5.72
-10.34%
-0.66
Autonomix Medical Enacts 1-for-21 Reverse Stock Split
TipRanks · 4d ago
Autonomix Medical enacts 1-for-21 reverse stock split effective June 24
PUBT · 4d ago
Autonomix Medical Inc trading halted, news pending
TipRanks · 4d ago
NASDAQ TRADE HALT <AMIX.O> HALT NEWS PENDING AT 07:50 PM
Reuters · 4d ago
Autonomix develops standalone neural sensing platform
TipRanks · 6d ago
AUTONOMIX MEDICAL ANNOUNCES STANDALONE NEURAL SENSING PROGRAM WITH EVIDENCE OF REAL-TIME RENAL NERVE ACTIVITY CHANGE
Reuters · 6d ago
Autonomix Medical announces standalone neural sensing platform after preclinical renal nerve activity results
PUBT · 6d ago
Weekly Report: what happened at AMIX last week (0615-0619)?
Weekly Report · 6d ago
Autonomix Announces 1-for-21 Reverse Stock Split Effective June 24
NASDAQ · 6d ago
Upcoming Stock Splits This Week (June 22 to June 26) – Stay Invested
TipRanks · 06/21 16:58
*Autonomix Medical to Effect a 1-For-21 Reverse Stk Split >AMIX
Dow Jones · 06/18 20:33
*Autonomix Medical: Reverse Stk Split Will Take Effect June 24 >AMIX
Dow Jones · 06/18 20:33
Autonomix Medical Announces 1-For-21 Reverse Stock Split, Effective June 24
Benzinga · 06/18 20:31
Autonomix Medical effects 1-for-21 reverse stock split June 24
PUBT · 06/18 20:30
AUTONOMIX MEDICAL - ANNOUNCES 1-FOR-21 REVERSE STOCK SPLIT
Reuters · 06/18 20:30
Autonomix Announces Reverse Stock Split
Barchart · 06/18 15:30
Weekly Report: what happened at AMIX last week (0608-0612)?
Weekly Report · 06/15 10:34
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 06/12 21:05
More
Webull provides a variety of real-time AMIX stock news. You can receive the latest news about Autonomix Medical Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMIX
Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.